Literature DB >> 32531156

Synthetic Access to Cannabidiol and Analogs as Active Pharmaceutical Ingredients.

Michael C Pirrung1,2.   

Abstract

Cannabinoids have surely been one of the most widely self-administered drugs other than caffeine. The U.S. FDA recently approved one cannabinoid-based drug whose active pharmaceutical ingredient (API) is cannabidiol (CBD). The long history of individual use of cannabis for a wide range of conditions has sparked great interest in other uses of CBD, in ethical drugs and botanical supplements as well as in foods and nonprescription wellness products. CBD may be sourced from cannabis plants but can also be prepared synthetically, the topic of this review.

Entities:  

Year:  2020        PMID: 32531156     DOI: 10.1021/acs.jmedchem.0c00095

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  1 in total

1.  Using (+)-Carvone to access novel derivatives of (+)-ent-Cannabidiol: the first asymmetric syntheses of (+)-ent-CBDP and (+)-ent-CBDV.

Authors:  Alexandra E Golliher; Antonio J Tenorio; Nina O Dimauro; Nicolas R Mairata; F Omar Holguin; William Maio
Journal:  Tetrahedron Lett       Date:  2021-02-05       Impact factor: 2.415

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.